Cargando…
Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
Histone deacetylase inhibitors (HDACi) are in clinical trials against a variety of cancers. Despite early successes, results against the more common solid tumors have been mixed. How is it that so many cancers, and most normal cells, tolerate the disruption caused by HDACi‐induced protein hyperacety...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091640/ https://www.ncbi.nlm.nih.gov/pubmed/27717012 http://dx.doi.org/10.1002/bies.201600070 |